Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 7c
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.73), $0.07 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $33.25 million versus the consensus estimate of $32.42 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold
- Rhythm Pharmaceuticals (RYTM) PT Raised to $151 at Canaccord
- JPMorgan Upgrades Visteon (VC) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
